Loading…
PAVmed Inc. is projected to decline to $6.11 by 2027, a -3% move from its current price of $6.30. PAVM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.09 | $6.30 | $6.53 | +0.07% |
| May 30 | $6.01 | $6.31 | $6.63 | +0.15% |
| May 31 | $5.94 | $6.31 | $6.71 | +0.22% |
| Jun 1 | $5.89 | $6.32 | $6.77 | +0.30% |
| Jun 2 | $5.85 | $6.32 | $6.84 | +0.37% |
| Jun 3 | $5.81 | $6.33 | $6.89 | +0.45% |
| Jun 4 | $5.78 | $6.33 | $6.94 | +0.52% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.78 | $6.33 | $6.94 | +0.52% |
| Week 2 | $5.59 | $6.37 | $7.25 | +1.04% |
| Week 3 | $5.46 | $6.40 | $7.51 | +1.57% |
| Week 4 | $5.35 | $6.43 | $7.73 | +2.10% |
| Week 5 | $5.26 | $6.47 | $7.94 | +2.63% |
| Week 6 | $5.19 | $6.50 | $8.14 | +3.16% |
| Week 7 | $5.12 | $6.53 | $8.34 | +3.70% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
PAVmed Inc. is a healthcare company that engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. Its lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device.
Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc.
in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
PAVmed Inc. (PAVM) is a healthcare company that trades in the market as PAVM. The current price is $6.39 and the market cap is $45.75M. The stock is ranked 4634 by market cap. The forecast presents a multi-year path with an average price that progresses across years, including a 2026 average of $6.39 and a 2050 average of $22.26, with a maximum projected price of $45.91 and an overall implied return of 248.4% by 2050.
The sentiment profile shifts from Neutral in the near term to Bullish in later years, reflecting a longer horizon upgrade.
A major floor 37.5% below — a decisive break under it would weaken the trend.
The nearest floor, 3.2% below — buyers have tended to step in here.
The nearest ceiling, 49.8% above — a clean break opens room to run.
A major ceiling 91.3% above — clearing it would confirm fresh momentum.
Key PAVM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PAVM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.26 | Buy | $6.29 | Buy |
| MA 10 | $6.32 | Sell | $6.45 | Sell |
| MA 20 | $6.98 | Sell | $6.97 | Sell |
| MA 50 | $8.48 | Sell | $8.04 | Sell |
| MA 100 | $8.95 | Sell | $9.02 | Sell |
| MA 200 | $10.52 | Sell | $11.69 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.51 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -61.81 | Neutral |
| Williams %R (14) | -81.13 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -12.01 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 18.87 | Buy |
| TRIX (15) | -1.31 | Sell |
| Awesome (5,34) | -1.63 | Sell |
| Ultimate (7,14,28) | 39.25 | Neutral |
| Momentum (10) | -0.20 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 6.25 | Buy |
| ADX (14) | 31.24 | Sell |
| ATR (14) | 0.25 | Info |
The 30-day technical picture shows a bearish stance with RSI (14) at 30. The price action is currently below the 50-day and 200-day simple moving averages, which stand at $8.63 and $10.58 respectively. Support is identified at $6.10 and resistance at $9.44.
Over the last 30 days, the price has traded between $5.05 and $8.09, highlighting meaningful short-term volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.10 | $6.30 | $8.31 | 0% | Neutral | |
| $4.71 | $6.11 | $8.45 | -3% | Neutral | |
| $5.86 | $7.86 | $11.37 | +25% | Bullish | |
| $6.02 | $8.33 | $12.46 | +32% | Bullish | |
| $5.75 | $8.17 | $12.59 | +30% | Bullish | |
| $6.00 | $8.74 | $13.81 | +39% | Bullish | |
| $5.29 | $7.89 | $12.74 | +25% | Bullish | |
| $5.18 | $7.89 | $13.01 | +25% | Bullish | |
| $5.49 | $8.54 | $14.35 | +36% | Bullish | |
| $5.89 | $9.36 | $16.00 | +49% | Bullish | |
| $6.27 | $10.94 | $20.11 | +74% | Bullish | |
| $10.62 | $21.89 | $44.67 | +248% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $6.10 | $6.30 | $7.40 | +0.00% |
| June 2026 | $5.43 | $6.42 | $7.79 | +1.85% |
| July 2026 | $5.64 | $6.74 | $8.32 | +5.05% |
| August 2026 | $5.51 | $6.64 | $8.30 | -1.55% |
| September 2026 | $5.32 | $6.45 | $8.16 | -2.78% |
| October 2026 | $5.43 | $6.63 | $8.46 | +2.74% |
| November 2026 | $5.45 | $6.69 | $8.60 | +0.87% |
| December 2026 | $5.19 | $6.40 | $8.31 | -4.23% |
Click any year to see its month-by-month PAVM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
PAVmed Inc.'s 2026 outlook centres on $6.30, within a $6.10 to $8.31 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, PAVM could reach as high as $8.45, with a base case around $6.11 and support toward $4.71 — roughly -3% from $6.30. Price action looks broadly range-bound.
Expect PAVM to range from $5.86 to $11.37 through 2028. The $7.86 average target implies a +25% move from current prices. That is up +29% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The PAVM price prediction for 2029 points to an average of $8.33 (low $6.02, high $12.46) — a potential gain of +32% on today's $6.30. Momentum favours further upside here.
In 2030, PAVM is projected to trade between $5.75 and $12.59, averaging $8.17 — a potential gain of +30% from today's $6.30. That is -2% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
PAVmed Inc.'s 2031 outlook centres on $8.74, within a $6.00 to $13.81 range. That is up +7% on the projected 2030 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2032, PAVM could reach as high as $12.74, with a base case around $7.89 and support toward $5.29 — roughly +25% from $6.30. Buyers look set to stay in control over this stretch.
Expect PAVM to range from $5.18 to $13.01 through 2033. The $7.89 average target implies a +25% move from current prices. That is up 0% on the projected 2032 average. Momentum favours further upside here.
The PAVM price prediction for 2034 points to an average of $8.54 (low $5.49, high $14.35) — a potential gain of +36% on today's $6.30. Buyers look set to stay in control over this stretch.
In 2035, PAVM is projected to trade between $5.89 and $16.00, averaging $9.36 — a potential gain of +49% from today's $6.30. That is up +10% on the projected 2034 average. Momentum favours further upside here.
PAVmed Inc.'s 2040 outlook centres on $10.94, within a $6.27 to $20.11 range. That is up +17% on the projected 2035 average. That marks a +74% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, PAVM could reach as high as $44.67, with a base case around $21.89 and support toward $10.62 — roughly +248% from $6.30. Momentum favours further upside here.
Investing $1,000 in PAVM today (≈ 158.730159 PAVM) could be worth
$3,475.33
+$2,475.33 (+248%) by 2050 · US Dollar
Based on the average projected PAVM price of $21.89 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PAVMwould be worth at today's price.
$1,000 invested in PAVM on May 27, 2025 (≈ 50.73567 PAVM) would be worth
$319.63
-$680.37 (-68.0%) today · 0.32× · US Dollar
Based on a PAVM entry price of $19.71 vs. today's $6.3.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.1 | $1,032.79 | +3.3% |
| 1 month ago | $8.4 | $750 | -25.0% |
| 3 months ago | $10.21 | $617.04 | -38.3% |
| 6 months ago | $11.07 | $569.11 | -43.1% |
| 1 year ago | $19.71 | $319.63 | -68.0% |
| All time (5.0y) ago | $2,394 | $2.63 | -99.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PAVM forecast.
Our base-case forecast reaches $13.00 around 2050.
Implied market cap at $13.00: $93.07M
Looking out to the multi-year forecast, the 2026 average is $6.39 with a neutral tone and the 2027 average is $6.25 with a -2.1% ROI, also neutral. Beginning in 2028 the outlook turns bullish, with 2028 average $8.01 (25.3% ROI), 2029 average $8.45 (32.3%), and 2030 average $8.36 (30.8%), followed by continued upside through 2031–2035 (averages ranging from $8.90 to $9.52 and ROI up to 49%). The 2040 forecast shows an average of $11.09 with a 73.6% ROI, and by 2050 the average is $22.26 with a 248.4% ROI, while the 2050 maximum is $45.91.
The forecast carries a bullish long-horizon tilt, but it also features a near-term dip in 2027 (ROI -2.1%), underscoring that outcomes are uncertain and not guaranteed. These figures are estimates of potential paths and should be treated as forward-looking projections rather than guarantees.
Tap a question to reveal the answer.
2030 avg $8.36 with a max of $12.96 and ROI of 30.8%; sentiment is BULLISH.
Near term shows Neutral sentiment in 2026 and 2027 with 0% and -2.1% ROI respectively, followed by BULLISH sentiment from 2028 onward, with higher ROIs through 2050 (e.g., 2050 ROI 248.4%). These are estimates and not guarantees.
The 2040 max is $20.58 and the 2050 max is $45.91, with the 2050 average at $22.26, indicating potential to approach or exceed $20 in later years.
Current price is $6.39 and market cap is $45.75M.
Bearish sentiment with RSI (14) at 30. The 30-day range is $5.05 to $8.09, with support at $6.10 and resistance at $9.44.
PAVmed Inc. Community Discussion
0Share your PAVmed Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.